TYME to Ring Nasdaq Opening Bell on November 27 to Honor All Stakeholders Committed to Finding a Cure for Patients with Pancreatic Cancer
November 25, 2019 08:00 ET
|
Tyme Technologies, Inc.
Pancreatic Cancer Expected to be the Second Leading Cause of Cancer-Related Death in the U.S. by 20201TYME’s oral SM-88 represents a new approach designed to selectively disrupt protein synthesis in...
Tyme Technologies to Present at the Evercore ISI HealthCONx Conference 2019
November 21, 2019 08:00 ET
|
Tyme Technologies, Inc.
NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management...
Tyme Technologies to Present at Jefferies 2019 London Healthcare Conference on November 20-21, 2019
November 07, 2019 08:00 ET
|
Tyme Technologies, Inc.
NEW YORK, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management...
TYME Presents Business Update and Reports Second Quarter Fiscal 2020 Financial and Operating Results
November 04, 2019 16:05 ET
|
Tyme Technologies, Inc.
Quarterly conference call today, November 4th, at 5 p.m. Eastern TimeUpdated Data From TYME-88-Panc PET Imaging and TYME-18 Preclinical Studies on Conference CallExpect Enrollment of Patients in the...
TYME Presents Business Update and Announces Second Quarter Fiscal 2020 Conference Call and Preliminary Operational Results
October 17, 2019 16:05 ET
|
Tyme Technologies, Inc.
TYME Launched the Pivotal Stage of TYME-88-PANC Trial to Evaluate Oral SM-88 for Third-Line Treatment of Patients with Metastatic Pancreatic CancerTYME Presented Final Data at ESMO 2019 from SM-88...
TYME Presented Updated Data at ESMO 2019 from SM-88 Phase II Prostate Cancer Study Demonstrating Encouraging Clinical Benefit in Patients with Recurrent Prostate Cancer
October 01, 2019 08:00 ET
|
Tyme Technologies, Inc.
Study results demonstrate that oral SM-88 may play a clinically meaningful role in postponing use of hormonal castration in prostate cancer patients with rising prostate-specific antigen (PSA): More...
TYME Presents Supporting Data at ESMO 2019 from TYME-88-Panc Phase II Study Demonstrating Overall Survival Trends, Well Tolerated Safety, and Quality of Life Data in Patients with Advanced Pancreatic Cancer
September 30, 2019 08:00 ET
|
Tyme Technologies, Inc.
TYME launched its multicenter randomized controlled pivotal stage of TYME-88-Panc trial for use of SM-88 in patients with third-line pancreatic cancer based on these clinical outcomesSM-88 is an oral,...
TYME Launches Pivotal Stage of TYME-88-PANC Trial to Evaluate SM-88 for Third-Line Treatment of Patients with Metastatic Pancreatic Cancer
September 25, 2019 08:00 ET
|
Tyme Technologies, Inc.
Oral SM-88 represents a new approach designed to selectively disrupt protein synthesis in cancers with demonstrated responses in 15 different cancer types across four separate studiesData presented at...
Tyme Technologies to Present at the Ladenburg Thalmann 2019 Healthcare Conference on September 24, 2019
September 17, 2019 08:00 ET
|
Tyme Technologies, Inc.
NEW YORK, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that...
TYME Presents Positive Circulating Tumor Cell Data from TYME-88-Panc Study in Patients with Advanced Pancreatic Cancer at AACR PANC 2019
September 09, 2019 08:00 ET
|
Tyme Technologies, Inc.
TYME-88-PANC Phase II study showed patients being treated with SM-88, who achieved at least an 80% reduction in circulating tumor cell burden, demonstrated a 60% decrease in risk of deathSM-88 is an...